Nuvation Bio is a clinical-stage oncology company focused on developing small molecule drugs for cancer patients with limited treatment options. Its lead product, IBTROZI (taletrectinib), is an oral, next-generation ROS1 tyrosine kinase inhibitor approved by the FDA in June 2025 for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer — a niche indication representing roughly 3,000 newly diagnosed U.S. patients per year. Nuvation sells IBTROZI directly in the U.S. through a focused team of 47 oncology account managers targeting academic centers, IDNs, and community practices, while relying entirely on third-party contract manufacturers for drug supply. Outside the U.S., Nuvation out-licenses IBTROZI to regional partners: Innovent in China, Nippon Kayaku in Japan, and Eisai across Europe and other territories, generating upfront payments, milestones, and royalties. Nuvation's pipeline includes safusidenib, a brain-penetrant oral inhibitor of mutant IDH1 in Phase 3 development for high-grade IDH1-mutant glioma — a population with no approved therapy — and NUV-1511, a Phase 1 drug-drug conjugate candidate for solid tumors. All three assets were originally in-licensed from Daiichi Sankyo, to whom Nuvation pays royalties on sales. Nuvation's commercial model benefits from duration stacking: patients remain on IBTROZI for extended periods, so each new cohort of patients adds to cumulative revenues over time.